Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
Crossref DOI link: https://doi.org/10.1007/s00228-016-2103-4
Published Online: 2016-08-06
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Stawowczyk, Ewa
Kawalec, Paweł
Pilc, Andrzej
License valid from 2016-08-06